Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome

References

• Gorodeski G. I., Utian W. H. Epidemiology and risk factors of cardiovascular disease in postmenopausal women. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, R. A. Lobo. Raven Press, New York 1994; 199–221
   Google Scholar
• Wild R. A., Grubb B., Hartz M. D., van Nort J. J., Bachman W., Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil. SteriL 1990; 54: 255–60
   PubMed Web of Science ®Google Scholar
• Wild R. A., Painter P. C., Coulson P. B., Car-Ruth B. K., Ranney G. B. Lipoprotein lipid concentrations and cardivascular risk in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1985; 61: 946–51
   PubMed Web of Science ®Google Scholar
• Wortsman J., Soler N. G. Abnormalities of fuel metabolism in the polycystic ovary syndrome. Obstet. Gynecol. 1982; 60: 342–5
   PubMed Web of Science ®Google Scholar
• Mattson L. A., Cullberg G., Hamberger L., Samsioe G., Silverstolpc G. Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk for coronary heart disease. Fertil. SteriL 1984; 42: 579–84
   PubMed Web of Science ®Google Scholar
• Dahlgren E., Johannson S., Lindstedt G., Knuts-Son F., Oden A., Janson P. O., Mattson L. A., Crona N., Lundberg P. A. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focussing on natural history and circulating hormones. Fertil. Steril. 1992; 57: 505–13
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol. (Oxf.) 1989; 31: 87–120
   PubMed Web of Science ®Google Scholar
• Chang R. J., Nakamura R. M., Judd H. L., Kaplan S. A. Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1983; 57: 356–9
   PubMed Web of Science ®Google Scholar
• Dunaif A., Mandeli J., Fluhr H., Dobrjansky A. The impact of obesity on chronic hy-perinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1988; 66: 131–9
   Google Scholar
• Conway G. S., Agrawal R., Betteridge D. J., Jacobs H. S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 1992; 37: 119–25
   PubMed Web of Science ®Google Scholar
• Björntorp P. Hyperandrogenicity in women-a prediabetic condition?. J. Intern. Med. 1993; 234: 579–83
   PubMedGoogle Scholar
• Dahlgren E., Janson P. O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 1992; 71: 599–604
   PubMed Web of Science ®Google Scholar
• Ferriman D., Gallwey J. D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 1961; 21: 1440–7
   PubMed Web of Science ®Google Scholar
• Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary heart disease (the PROCAM experience). Am. J. Cardiol. 1992; 70: 733–7
   PubMed Web of Science ®Google Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultracentnfuge. Clin. Chem. 1972; 18: 499–508
   PubMed Web of Science ®Google Scholar
• Sandkamp M. B. Tambyrajah, Schriewer H., Assmann G. Simplified turbidimetric determination of apolipoproteins A-I, A-II and B using a microtitre method. J. Clin. Chem. Clin. Biochem. 1988; 26: 685–9
   PubMedGoogle Scholar
• Sandkamp M., Funke H., Schulte H., Köhler E., Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin. Chem. 1990; 38: 20–5
   Google Scholar
• Hill J. S., Pritchard P. H. Improved phenotyping of apolipoprotein E: application to population frequency distribution. Clin. Chem. 1990; 36: 1871–4
   PubMedGoogle Scholar
• Lüttmann S., von Eckardstein A., Wei W., Funke H., Köhler E., Mahley R. W., Assmann G. Electrophoretic screening for genetic variation in apo C–III: identification of a novel apo C-III-variant, apo C-III(Asp45-→Asn). J. Lipid Res. 1994; 35: 1431–40
   PubMedGoogle Scholar
• International Task Force for the Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc. Dis. 1992; 2: 113–56
   Google Scholar
• Lenzen H. J., Assmann G., Buchwalsky R., Schulte H. Association of apolipoprotein E polymorphism, low density lipoprotein cholesterol and coronary artery disease. Clin. Chem. 1986; 32: 778–84
   PubMed Web of Science ®Google Scholar
• Rojanasakul A., Chailurkit L., Sirimongkol-Kasem R., Chaturachinda K. Serum lipids and lipoproteins in women with polycystic ovarian disease with different body mass index. Int. J. Gynaecol. Obstet. 1988; 27: 401–6
   PubMedGoogle Scholar
• Kim H. J., Kalkhoff R. K. Changes in lipoprotein composition during the menstrual cycle. Metabolism 1979; 28: 663–8
   PubMed Web of Science ®Google Scholar
• Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Tliromb. Vase. Biol. 1995; 15: 821–6
   PubMed Web of Science ®Google Scholar
• Holte J., Bergh T., Berne C., Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin. Endocrinol. (Oxf.) 1994; 41: 463–71
   PubMed Web of Science ®Google Scholar
• Clayton R. N., Ogden V., Hodgkinson J., Wor-Swick L., Rodin D. A., Dyer S., Meade T. W. How common are polycystic ovaries in normal women and what is their significance for the fetility of the population. Clin. Endocrinol. (Oxf.) 1992; 37: 127–34
   PubMed Web of Science ®Google Scholar
• Conway G. S., Clark P. M., Wong D. Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific im-munoradiometric assay for insulin. Clin. Endocrinol. (Oxf) 1993; 38: 219–22
   PubMedGoogle Scholar
• Graf M. J., Richards C. J., Brown V., Meissner L., Dunaif A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin. Endocrinol. (Oxf) 1990; 33: 119–31
   PubMedGoogle Scholar
• Davignon J., Gregg R. E., Sing C. F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1–21
   PubMedGoogle Scholar
• Dallongeville J., Lussier-Cacan S., Davignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta analysis. J. Lipid Res. 1992; 33: 447–54
   PubMed Web of Science ®Google Scholar
• Heller D. A., deFaire U., Perdeson N. L., Dahlen G., McClearn G. E. Genetic and environmental influences on serum lipid levels in twins. N. Engl. J. Med. 1993; 328: 1150–6
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch. Intern. Med. 1988; 148: 36–69
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein, and Coronary Heart Disease. J. Am. Med. Assoc 1993; 269: 505–10
   Google Scholar